Breaking Q2 Financial Results: Gentherm and Esperion Beat Expectations
- August 01st, 2023
- 319 views
Gentherm Incorporated (Nasdaq: THRM) reported strong second quarter 2023 adjusted earnings per share (EPS) of $0.58, surpassing the consensus estimate of $0.52, and revenues of $372.30 million, beating the analysts' expectation of $368.63 million.
The company reaffirmed its full-year 2023 guidance, expecting product revenues between $1.45 billion and $1.55 billion, against a consensus estimate of $1.51 billion for the period.
In pre-market, $THRM was trading at $60.38, reflecting a gain of $0.61 (+1.02%).
In other news, Esperion Therapeutics, Inc. (Nasdaq: ESPR) delivered better-than-expected financial results.
The company reported a Q2 2023 loss of $0.46 per share, outperforming the consensus estimate of a loss of $0.61 per share, and revenues of $25.79 million, surpassing the analysts' forecast of $24.64 million for the period.
In pre-market trading, $ESPR was at $1.70, showing a gain of $0.13 (+8.28%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login